Liudmila Zotova

Dr. Liudmila Zotova

Ryazan State Medical University named after Academician I.P. Pavlov, Ryazan, Ryazanskaya Oblast’, Russia
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
LZLiudmila Zotova
Liudmila Zotova
Myocarditis associated with the use of immune checkpoint inhibitors (ICI) is a rare manifestation of their cardiotoxicity, but is characterized by a high mortality rate. A literature search was conducted using PubMed using keywords, which resulted in the selection of 679 scientific works, from which 160 articles that described 244 clinical cases were selected. The median age of the patients was 67 years (IQR, 60–74). The median time from the start of ICI therapy to the development of the first adverse symptoms was 21 days (IQR, 14–38.3). In 37% of cases, myocarditis developed after the first administration of ICI. Cardiac symptoms were present in 47.1% of cases, neuromuscular symptoms in 30.3%, and other symptoms in 12.6%, while myocarditis was asymptomatic in 10.1% of cases. New changes in the electrocardiograms were detected in 85.1% of patients compared to the initial data. A high incidence of complete atrioventricular block (25.4%), right bundle branch block (18.4%), ventricular tachycardia (13%), and sinus tachycardia (12%) were noted. In 97% of the cases, the patients received prednisolone or methylprednisolone therapy. When using ICI, special attention should be paid to the early detection of possible cardiotoxicity by analyzing the condition and function of the myocardium before treatment and its dynamics.

8 July 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
EFE. V. Filippov
E. V. Filippov
AVA. N. Vorobyev
A. N. Vorobyev
NDN. V. Dobrynina
N. V. Dobrynina
LZLiudmila Zotova
Liudmila Zotova
ELE. V. Lygina
E. V. Lygina
SYSergey S. Yakushin
Sergey S. Yakushin
Неблагоприятные сердечно-сосудистые исходы и их связь с факторами риска по данным проспективного исследования МЕРИДИАН-РО

26 September 2025 in World Journal of Cardiology
Verified
Journal Article
Open access
LZLiudmila Zotova
Liudmila Zotova
NENikita V Enenkov
Nikita V Enenkov
Rheumatoid arthritis (RA) significantly increases the risk of cardiovascular diseases (CVD), including myocardial infarction (MI), stroke, and heart failure (HF). This association is linked to chronic inflammation, endothelial dysfunction, and accelerated atherosclerosis. Patients with RA have a 1.5-2 times higher risk of CVD compared to the general population, and cardiovascular mortality reaches 40%-50%. However, basic anti-inflammatory drugs such as methotrexate reduce the rate of cardiovascular events by 20%-30% due to suppression of systemic inflammation. Biological medications also demonstrate a cardioprotective effect, reducing the risk of MI by 20%-40%, although some (e.g. , tumor necrosis factor α inhibitors) may increase the risk of HF in predisposed patients. Janus kinase inhibitors are associated with an increased risk of thrombosis and cardiovascular events, particularly in patients with pre-existing risk factors. Therefore, optimal control of inflammation in RA can reduce cardiovascular risk; however, drug selection should consider individual safety profiles. Regular monitoring of cardiovascular risk factors and a multidisciplinary approach are key to managing patients with RA and minimizing complications.

14 November 2023 in Biologics
Verified
Journal Article
Open access
PDF file
LZLiudmila Zotova
Liudmila Zotova
VKVictoria Kotova
Victoria Kotova
ZKZakhar Kuznetsov
Zakhar Kuznetsov
The diagnosis of systemic autoimmune rheumatic disease (SARD) or its exclusion is carried out taking into account the results of immunological studies, primarily antinuclear antibodies (ANA) and specific autoantibodies. Often, during ANA analysis via indirect immunofluorescence reaction on cellular and tissue substrates, a dense fine speckled 70 (DFS70) fluorescence pattern is observed. Studies on the diagnostic significance of antibodies to anti-DFS70 allow for optimizing the stepwise diagnosis of SARD. Currently, a two-step strategy for laboratory diagnostic investigation is recommended: in the first step, ANA screening is performed, and in the second step, patients with positive results undergo confirmatory tests to detect specific antibodies against individual nuclear antigens. The detection of anti-DFS70 in ANA-seropositive patients without clinical and/or other specific serological markers characteristic of a particular disease within the SARD group may be considered a negative prognostic marker. Also, in the process of decision making in clinical practice, we should remember that anti-DFS70 can be found in the blood of patients with a different, non-SARD pathology and that most people showing anti-DFS70 are healthy individuals.

15 March 2013 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Open access
PDF file
LZLiudmila Zotova
Liudmila Zotova
Dilated cardiomyopathy - the primary lesion of the myocardium due to various reasons, characterized by a pronounced expansion of the heart chambers and decreased systolic and diastolic functions. Among the etiological causes in the first place should include a genetic predisposition. Diagnosis of the disease involves the identification of specific changes in echocardiography and the exclusion of other causes of heart failure. Therapy is symptomatic. Questions such as prediction of disease, improved survival, pathogenetic therapy, still await solution.

1 January 2022 in Современные проблемы науки и образования (Modern Problems of Science and Education)
Verified
Journal Article
Open access
LZLiudmila Zotova
Liudmila Zotova
SYS.S. Yakushin
S.S. Yakushin